These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
251 related articles for article (PubMed ID: 34215703)
1. Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea. Tanaka Y; Bae SC; Bass D; Curtis P; Chu M; DeRose K; Ji B; Kurrasch R; Lowe J; Meizlik P; Roth DA RMD Open; 2021 Jul; 7(2):. PubMed ID: 34215703 [TBL] [Abstract][Full Text] [Related]
2. A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea. Zhang F; Bae SC; Bass D; Chu M; Egginton S; Gordon D; Roth DA; Zheng J; Tanaka Y Ann Rheum Dis; 2018 Mar; 77(3):355-363. PubMed ID: 29295825 [TBL] [Abstract][Full Text] [Related]
3. Long-term safety and efficacy of belimumab in Japanese patients with SLE: A 7-year open-label continuation study. Tanaka Y; Curtis P; DeRose K; Kurrasch R; Kinoshita K; Tanaka R; Yamazaki Y; Roth DA Mod Rheumatol; 2023 Jan; 33(1):122-133. PubMed ID: 34915574 [TBL] [Abstract][Full Text] [Related]
4. Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years. Zhang F; Zheng J; Li Y; Wang G; Wang M; Su Y; Gu J; Li X; Bass D; Chu M; Curtis P; DeRose K; Kurrasch R; Lowe J; Meizlik P; Roth DA RMD Open; 2022 Apr; 8(1):. PubMed ID: 35428697 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of intravenous belimumab in a subgroup of South Korean patients with systemic lupus erythematosus enrolled into a Phase 3, randomized, placebo-controlled trial in North East Asia. Suh CH; Lee Y; Yoo SB; Quasny H; Navarro Rojas AA; Hammer A; Song YW; Kang YM; Cho CS; Park W; Kwok SK; Lee SG; Chung WT; Bae SC Int J Rheum Dis; 2024 Jan; 27(1):e14997. PubMed ID: 38140854 [TBL] [Abstract][Full Text] [Related]
6. Long-Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus: A Continuation of a Seventy-Six-Week Phase III Parent Study in the United States. Furie RA; Wallace DJ; Aranow C; Fettiplace J; Wilson B; Mistry P; Roth DA; Gordon D Arthritis Rheumatol; 2018 Jun; 70(6):868-877. PubMed ID: 29409143 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study. Stohl W; Schwarting A; Okada M; Scheinberg M; Doria A; Hammer AE; Kleoudis C; Groark J; Bass D; Fox NL; Roth D; Gordon D Arthritis Rheumatol; 2017 May; 69(5):1016-1027. PubMed ID: 28118533 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison. Brunner HI; Abud-Mendoza C; Mori M; Pilkington CA; Syed R; Takei S; Viola DO; Furie RA; Navarra S; Zhang F; Bass DL; Eriksson G; Hammer AE; Ji BN; Okily M; Roth DA; Quasny H; Ruperto N RMD Open; 2021 Sep; 7(3):. PubMed ID: 34531304 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Subcutaneous Belimumab in Anti-Double-Stranded DNA-Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus. Doria A; Stohl W; Schwarting A; Okada M; Scheinberg M; van Vollenhoven R; Hammer AE; Groark J; Bass D; Fox NL; Roth D; Gordon D Arthritis Rheumatol; 2018 Aug; 70(8):1256-1264. PubMed ID: 29671280 [TBL] [Abstract][Full Text] [Related]
10. Organ system improvements in Japanese patients with systemic lupus erythematosus treated with belimumab: A subgroup analysis from a phase 3 randomized placebo-controlled trial. Tanaka Y; Bass D; Chu M; Egginton S; Ji B; Roth D Mod Rheumatol; 2020 Mar; 30(2):313-320. PubMed ID: 31199180 [No Abstract] [Full Text] [Related]
11. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Furie R; Petri M; Zamani O; Cervera R; Wallace DJ; Tegzová D; Sanchez-Guerrero J; Schwarting A; Merrill JT; Chatham WW; Stohl W; Ginzler EM; Hough DR; Zhong ZJ; Freimuth W; van Vollenhoven RF; Arthritis Rheum; 2011 Dec; 63(12):3918-30. PubMed ID: 22127708 [TBL] [Abstract][Full Text] [Related]
12. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. Ginzler EM; Wallace DJ; Merrill JT; Furie RA; Stohl W; Chatham WW; Weinstein A; McKay JD; McCune WJ; Zhong ZJ; Freimuth WW; Petri MA; J Rheumatol; 2014 Feb; 41(2):300-9. PubMed ID: 24187095 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of belimumab in patients with systemic lupus erythematosus from North East Asia: Results of exploratory subgroup analyses. Zheng J; Gu J; Su Y; Li Y; Li X; Xiong C; Cao H; Quasny H; Chu M; Curtis P; DeRose K; Kurrasch R; Meizlik P; Roth DA; Zhang F Mod Rheumatol; 2023 Jul; 33(4):751-757. PubMed ID: 36208293 [TBL] [Abstract][Full Text] [Related]
14. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Wallace DJ; Stohl W; Furie RA; Lisse JR; McKay JD; Merrill JT; Petri MA; Ginzler EM; Chatham WW; McCune WJ; Fernandez V; Chevrier MR; Zhong ZJ; Freimuth WW Arthritis Rheum; 2009 Sep; 61(9):1168-78. PubMed ID: 19714604 [TBL] [Abstract][Full Text] [Related]
15. Phase III/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus. Ginzler E; Guedes Barbosa LS; D'Cruz D; Furie R; Maksimowicz-McKinnon K; Oates J; Santiago MB; Saxena A; Sheikh S; Bass DL; Burriss SW; Gilbride JA; Groark JG; Miller M; Pierce A; Roth DA; Ji B Arthritis Rheumatol; 2022 Jan; 74(1):112-123. PubMed ID: 34164944 [TBL] [Abstract][Full Text] [Related]
16. A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus. Doria A; Bass D; Schwarting A; Hammer A; Gordon D; Scheinberg M; Fox NL; Groark J; Stohl W; Kleoudis C; Roth D Lupus; 2018 Aug; 27(9):1489-1498. PubMed ID: 29807477 [TBL] [Abstract][Full Text] [Related]
17. The effect of 24-week belimumab treatment withdrawal followed by treatment restart in patients with SLE: an open-label, non-randomised 52-week study. Bae SC; Bass DL; Chu M; Curtis P; Dimelow R; Harvey L; Ji B; Kurrasch R; Muzaffar S; Punwaney R; Roth DA; Song YW; Xie W; Zhang F Arthritis Res Ther; 2022 Feb; 24(1):46. PubMed ID: 35172878 [TBL] [Abstract][Full Text] [Related]
18. Efficacy of belimumab in two serologically distinct high disease activity subgroups of patients with systemic lupus erythematosus: post-hoc analysis of data from the phase III programme. Maslen T; Bruce IN; D'Cruz D; Ianosev M; Bass DL; Wilkinson C; Roth DA Lupus Sci Med; 2021 Feb; 8(1):. PubMed ID: 33568389 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Navarra SV; Guzmán RM; Gallacher AE; Hall S; Levy RA; Jimenez RE; Li EK; Thomas M; Kim HY; León MG; Tanasescu C; Nasonov E; Lan JL; Pineda L; Zhong ZJ; Freimuth W; Petri MA; Lancet; 2011 Feb; 377(9767):721-31. PubMed ID: 21296403 [TBL] [Abstract][Full Text] [Related]
20. Impact of concomitant medication use on belimumab efficacy and safety in patients with systemic lupus erythematosus. Schwarting A; Dooley MA; Roth DA; Edwards L; Thompson A; Wilson B Lupus; 2016 Dec; 25(14):1587-1596. PubMed ID: 27488472 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]